55837-25-7|Buflomedil|1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-|-范德生物科技公司

Buflomedil

NMR下载 COA and HPLC MSDS下载
names：
1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-
CAS号：
55837-25-7
MDL Number：
MF(分子式)： C17H25NO4 MW(分子量)： 307.39
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Buflomedil
英文别名	Buflomedil; Buflomedilum
CAS号	55837-25-7
Inchi	InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3
InchiKey	OWYLAEYXIQKAOL-UHFFFAOYSA-N
分子式 Formula	C17H25NO4
分子量 Molecular Weight	307.39
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Buflomedil(CAS:55837-25-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Buflomedil is a vasoactive agent that has been used for peripheral arterial diseases.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]de Backer TL, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD000988. doi: 10.1002/14651858.CD000988.pub4. Review. PubMed PMID: 23543509.

[2]Bucolo C, Longo L, Camillieri G, Drago F, Salomone S. Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011. Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1190-6. doi: 10.1002/pds.3328. Epub 2012 Jul 31. Review. PubMed PMID: 22855302.

[3] Tsantilas D, Hatzitolios AI, Tziomalos K, Karamitsos D, Papadimitriou D. Effects of buflomedil on skin blood flow in patients with type 2 diabetes mellitus without overt micro- or macroangiopathy. Int Angiol. 2011 Apr;30(2):164-71. PubMed PMID: 21427654.

[4] Wu S, Zeng Q, Liu M, Yang J, He S, Lin S, Wu B. Buflomedil for acute ischaemic stroke. Cochrane Database Syst Rev. 2015 Jul 20;(7):CD009570. doi: 10.1002/14651858.CD009570.pub2. Review. PubMed PMID: 26193704.

[5] El-Desoky HS, Ghoneim MM, Abdel-Galeil MM. Quantification of the Vasoactive Agent Buflomedil HCl in Pharmaceutical Formulation and Human Serum by Stripping Voltammetry and Liquid Chromatography. Acta Chim Slov. 2010 Jun;57(2):332-40. PubMed PMID: 24061728.

6: Papa P, Rocchi L, Mainardi C, Donzelli G. Buflomedil interference with the monoclonal EMIT d.a.u. amphetamine/methamphetamine immunoassay. Eur J Clin Chem Clin Biochem. 1997 May;35(5):369-70. PubMed PMID: 9189741.7: Le Dévéhat C, Vimeux M, Bondoux G, Khodabandehlou T. Effects of buflomedil on microvascular disorders in diabetic patients. Blood Vessels. 1991;28 Suppl 1:38-43. PubMed PMID: 1932765.8: Tang JR, Wu L, Su JH, Zhang P, Yu LB, Xiao H. Vasoactive agent buflomedil up-regulated expression of vascular endothelial growth factor in a rat model of sciatic nerve crush injury. Indian J Pharmacol. 2012 Jul-Aug;44(4):480-4. doi: 10.4103/0253-7613.99312. PubMed PMID: 23087509; PubMed Central PMCID: PMC3469951.9: Kushiku K, Ohba M, Mikagi T, Nuki S, Araki Y, Furukawa T. Cardiovascular actions of buflomedil and possible mechanisms involved. Arzneimittelforschung. 1989 Jun;39(6):670-7. PubMed PMID: 2775333.10: de Backer TL, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000988. doi: 10.1002/14651858.CD000988.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开